AzTrials
AzTrials

Institutionalized Older AdultsMUR'AVENTURENCT07809087

Feasibility Study of an Interactive Wall-Based Intervention Program for Nursing Home Residents and Patients in Long-Term Care Facilities: Mur'Aventure

A study testing Immersive Interactive Wall Exergame Program in people with Institutionalized Older Adults, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This prospective, single-arm feasibility study aims to evaluate the feasibility of a 12-week immersive exergame program using an interactive wall in older adults living in nursing homes (EHPAD) or long-term care units (USLD). Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Institutionalized Older Adults
What is being tested?
Immersive Interactive Wall Exergame Program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteFrance
Study dates
Oct 2026to Sep 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Adults aged 65 years or older.
  • Resident of a nursing home (EHPAD) or long-term care unit (USLD).
  • Affiliated with the French national health insurance system.
  • Able to participate in low-to-moderate intensity adapted physical activity.
  • No cognitive impairment or mild-to-moderate cognitive impairment compatible with understanding simple instructions (MoCA >18 and physician approval).
  • Written informed consent provided by the participant or legal representative.

Who cannot join

  • Medical contraindication to adapted physical activity.
  • Severe neurological or psychiatric disorder incompatible with safe participation.
  • Severe uncorrected visual, auditory or sensory impairment preventing interaction with the immersive wall.
  • Inability to understand instructions despite adaptation.
  • Participation in another interventional study that may interfere with study outcomes.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Elodie Piche, PhD contact

+33492034925

piche.e@chu-nice.fr

Assia Bebiche Lamali, MD contact

+33492034925

bebiche-lamali.a@chu-nice.fr

France1 site
  • CHU de Nice

    Nice

    Elodie Piche, PhD, +33492034925, piche.e@chu-nice.fr

    Assia Bebiche Lamali, MD

Other trials in France

About this study

This prospective, single-arm feasibility study aims to evaluate the feasibility of a 12-week immersive exergame program using an interactive wall in older adults living in nursing homes (EHPAD) or long-term care units (USLD). Exergames are interactive digital games that integrate physical activity into gameplay, requiring users to perform whole-body movements to achieve game objectives while promoting exercise and energy expenditure. Participants will complete two supervised 40-minute sessions per week over 12 weeks. The primary objective is to assess feasibility through acceptability, adherence, and safety. Secondary objectives include evaluating implementation fidelity, preliminary effects on cognition, quality of life and well-being, and characterizing the physical and cognitive demands of the interactive games. Data will include usability and enjoyment questionnaires, attendance, adverse events, heart rate monitoring, cognitive performance (MoCA), quality of life (EQ-5D-5L), psychological well-being (Mini-GDS and QUALIDEM), and game performance. The results will inform the design of a future larger-scale effectiveness trial of immersive exergaming in institutionalized older adults.

Being tested
Immersive Interactive Wall Exergame Program
Keywords
immersive exergame, older adults, cognition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Immersive Interactive Wall Exergame ProgramBehavioural

    Participants will complete a supervised 12-week adapted physical activity program delivered through an immersive interactive wall (NeoXperience). Sessions will be performed twice weekly in groups of four participants and will last approximately 40 minutes, including a warm-up. Games are adapted to participants' physical and cognitive abilities and combine cognitive stimulation with whole-body movements. Heart rate, physical activity intensity, game performance, perceived exertion, fatigue and enjoyment will be monitored throughout the intervention.

Study groups in NCT07809087
Study groupRoleWhat they receive
Immersive Interactive Wall Exergame Program (Mur'Aventure)ExperimentalNot described
Receives: Behavioral: Immersive Interactive Wall Exergame Program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Acceptability of the Mur'Aventure program assessed using the French System Usability Scale (F-SUS)

    Acceptability will be assessed using the French version of the System Usability Scale (F-SUS), a validated 10-item questionnaire evaluating the perceived usability of a system. Total scores range from 0 to 100, with higher scores indicating greater usability and acceptability. Acceptability will be considered achieved if at least 70% of participants obtain a score >70.

    Feasibility will be considered successful if all three predefined feasibility criteria (acceptability, adherence, and safety) are met. If one or more criteria are not met, the feasibility of the intervention will be interpreted in light of the unmet criterion(ia), and potential modifications to the intervention or study procedures will be discussed.

    Measured: During the 12-week intervention and immediately after the intervention.

Secondary outcomes (11)
  1. Program adherence : predefined feasibility criteria

    Adherence will be evaluated by the completion rate, defined as the proportion of participants completing the entire 12-week intervention. Adherence will be considered good if the completion rate is ≥70%. Attendance rate and dropout rate will also be reported descriptively.

    Measured: Throughout the 12-week intervention.

  2. Safety of the Mur'Aventure program : predefined feasibility criteria

    Safety will be assessed by recording the occurrence of serious adverse events (SAEs) throughout the intervention. Safety will be considered acceptable if no serious adverse events related to the intervention occur. Additional descriptive safety measures include perceived fatigue, perceived exertion, and heart rate responses recorded during each intervention session.

    Measured: Throughout the 12-week intervention

  3. Intervention fidelity

    To describe the fidelity of program implementation, assessed by the proportion of intervention sessions delivered according to the planned protocol Intervention fidelity will be assessed as the percentage of planned exercise sessions completed according to the study protocol. Higher percentages indicate greater fidelity to the intervention.

    Measured: Throughout the 12-week intervention

  4. Change in Montreal Cognitive Assessment (MoCA) total score

    To explore the preliminary effects of the program on cognitive function, assessed by the change in the Montreal Cognitive Assessment (MoCA) total score Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a validated 30-point cognitive screening instrument evaluating memory, executive function, attention, language, visuospatial abilities, abstraction, and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive function. The outcome is the change in total score between baseline and the end of the intervention.

    Measured: Baseline and immediately after the 12-week intervention

  5. Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) score

    To explore the preliminary effects of the program on health-related quality of life, assessed by the change in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) score from baseline to post-intervention.

    Health-related quality of life will be assessed using the EQ-5D-5L questionnaire, which evaluates mobility, self-care, usual activities, pain/discomfort, and anxiety/depression across five severity levels. Responses are converted into an EQ-5D index value, with higher index values indicating better health-related quality of life. The change in EQ-5D index score between baseline and the end of the intervention will be analyzed

    Measured: Baseline and immediately after the 12-week intervention

  6. Change in Mini-Geriatric Depression Scale (Mini-GDS) score

    To explore the preliminary effects of the program on self-reported psychological well-being, assessed by the change in the 4-item Mini-Geriatric Depression Scale (Mini-GDS) score from baseline to post-intervention.

    Psychological well-being will be assessed using the 4-item Mini-Geriatric Depression Scale (Mini-GDS). Scores range from 0 to 4, with higher scores indicating more depressive symptoms and poorer psychological well-being. The outcome is the change in total score between baseline and the end of the intervention

    Measured: Baseline and immediately after the 12-week intervention.

  7. Change in QUALIDEM total score

    To explore the preliminary effects of the program on caregiver-observed well-being, assessed by the change in the French version of the QUALIDEM total score from baseline to post-intervention.

    Observed well-being will be assessed using the French version of the QUALIDEM questionnaire, a proxy-rated instrument evaluating quality of life in older adults with cognitive impairment.

    Higher score indicating better quality of life. The outcome is the change in total score between baseline and the end of the intervention.

    Measured: Baseline and immediately after the 12-week intervention.

  8. Mean heart rate during intervention sessions

    To describe the physical stimulation induced by the intervention sessions, assessed using heart rate and measured during each session with the Polar Unite wearable device Heart rate will be continuously recorded during each exercise session using a Polar Unite heart rate monitor. Mean heart rate (beats per minute) as well as maximal heart rate will be calculated for each participant during each session. Higher values indicate greater cardiovascular response to exercise.

    Measured: During each intervention session throughout the 12-week intervention.

  9. Cognitive stimulation during the intervention

    To describe cognitive stimulation during the intervention, assessed using the game score, number of errors, and completion time automatically recorded during each session Cognitive stimulation will be assessed using the total score, number of errors and completion time automatically recorded by the Mur'Aventure interactive wall software during each exercise session. Higher scores indicate better cognitive stimulation.

    Measured: During each intervention session throughout the 12-week intervention

  10. Mean physical load during intervention sessions

    To describe the physical stimulation induced by the intervention sessions, assessed using heart rate and physical load measured during each session with the Polar Unite wearable device Physical load will be estimated using the Polar Unite wearable device. The device provides a proprietary estimate of exercise load based on heart rate and movement data recorded during each session. Higher values indicate greater physical exercise load.

    Measured: During each intervention session throughout the 12-week intervention.

  11. Game engagement during the intervention

    To describe game engagement during the intervention, assessed using the game score, number of errors, and completion time automatically recorded during each session Game engagement will be assessed using the total score, number of errors and completion time automatically recorded by the Mur'Aventure interactive wall software during each exercise session. Higher scores indicate better game performance.

    Measured: During each intervention session throughout the 12-week intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Sep 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionJan 2028 (estimated)
  4. Study completionSep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
25 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07809087
Sponsor's protocol ID
[25-AOIP-06
Acronym
MUR'AVENTURE
Status last verified
Sep 2026
First submitted
23 Jul 2026
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Immersive Interactive Wall Exergame Program in people with Institutionalized Older Adults, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Elodie Piche, PhD (+33492034925, piche.e@chu-nice.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Acceptability of the Mur'Aventure program assessed using the French System Usability Scale (F-SUS) (time frame: During the 12-week intervention and immediately after the intervention.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in